Trial Profile
A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB IV
- Sponsors Abbott Vascular
- 13 May 2023 Results assessing the long term (5-year) clinical outcomes, published in the Journal of the American College of Cardiology.
- 08 Jul 2022 Status changed from active, no longer recruiting to completed.
- 24 Sep 2019 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2022.